4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics is a late-stage biotechnology company developing durable and disease-targeted therapies. The company's products are developed using customized and evolved adeno-associated virus ("AAV") vectors, which are invented from its proprietary Therapeutic Vector Evolution ("TVE") platform. TVE is designed to create vectors that overcome the limitations of conventional AAV vectors by applying directed evolution principles in non-human primate ("NHP") models. This process selects vectors that target tissues of diseases with high unmet need using routine and local administration routes. The company focuses on clinical-stage product candidates for retina and lung conditions, utilizing vectors invented with TVE. Its lead product candidate, 4D-150, uses the proprietary R100 vector and a transgene encoding anti-VEGF biologics: aflibercept (targeting VEGF-A, VEGF-B, and placental growth factor) and an RNA interference (RNAi) approach targeting VEGF-C. 4D-150 is being developed to treat wet age-related macular degeneration ("wet AMD") and diabetic macular edema ("DME"). Another pipeline program, 4D-710, is a genetic medicine designed to deliver and express the cystic fibrosis transmembrane conductance regulator ("CFTR") transgene in the lungs of people with cystic fibrosis ("CF") and is currently in Phase 2 development.